Skip to main content
Download PDF

The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer

European Journal of Medical Research volume 18, Article number: 56 (2013) Cite this article

Abstract

Background

Prostate stem cell antigen (PSCA) is upregulated in prostate cancer tissues. Here we aimed to study the therapeutic efficacy of a monoclonal antibody of PSCA-labeled I131 (I131-PSCA-mAb) in orthotopic mouse models of prostate cancer.

Methods

The proliferation, apoptosis and invasion abilities of PC-3 and LNCaP cells treated with I131-PSCA-mAb were measured by methyl thiazolyl tetrazolium assay, flow cytometry and transwell culture, respectively. The human prostate cancer models were established by orthotopic implantation of PC-3 and LNCaP cells in nude mice. I131-PSCA-mAb distribution and tumor cell apoptosis in the tumor-bearing nude mice were measured.

Results

The inhibitory and apoptosis rates of PC-3 and LNCaP cells treated with I131-PSCA-mAb reached a maximum of 84%, 80% and 50%, 46%, respectively, which were obviously higher than in the cells treated with I131-IgG or PSCA-mAb. The invaded number of PC-3 and LNCaP cells treated with I131-PSCA-mAbe was significantly reduced (P < 0.01) compared with the control group. The ratios of I131-PSCA-mAb in tumor to intramuscular I131-PSCA-mAb (T/NT) in tumor-bearing nude mice were increased with time and reached the highest level after 8 h. T/NT stayed above 3.0 after 12 h, and the tumor could still be developed after 24 h. The number of apoptotic cells in tumor tissue of nude mice treated with I131-PSCA-mAb was larger than that in the control group.

Conclusion

I131-PSCA-mAb has the potential to become a new targeted therapy drug for the treatment of prostate cancer.

Background

Prostate cancer is one of the most frequently diagnosed malignancies worldwide and has become one of the leading causes of cancer-related death in men, only behind lung cancer [1, 2]. Some patients with metastatic disease die within 2–3 years of diagnosis, whereas others with organ-confined disease can live for 10–20 years, which indicates that prostate tumors might have tremendous genomic diversity [3].

Androgens could contribute to the initial growth of prostate cancer [4]. In 1941, Huggins and Hodges successfully applied androgen deprivation therapy (ADT) by the injection of estrogens in metastatic prostate cancer patients in the form of surgical castration [5, 6]. Within 1–2 years after initial response, progression of prostate cancer typically occurs; ADT could be considered as the treatment of choice for patients with advanced metastatic prostate cancer [7, 8]. However, most prostate tumors ultimately progress to hormone-resistant prostate cancer (HRPC), which is androgen-independent growth, and resistance inevitably occurs within a few years, while antiandrogen therapy is initially effective [9]. Though early detection and treatment have improved significantly, biochemical recurrence might happen to almost 40% of men after radical retropubic prostatectomy [10]. The clinical manifestations of HRPC include increased concentrations of prostate serum antigen (PSA), bone metastases, soft-tissue/lymph node metastases and substantive pain [11].

Prostate stem cell antigen (PSCA) belongs to the Thy-1/Ly-6 family of the glycosylphosphatidylinositol-anchored cell membrane glycoprotein, which can overexpress in prostate cancer tissues [12]. Although PSCA expression has been detected in all stages of prostate cancer, the increased expression level of PSCA is positively correlated with biochemical recurrence, advanced stage, transition to the castration-resistant state and metastatic progression [13–16]. Ahmad et al. reported that a plasmid-based vaccine against PSCA may have the potential to be used in multimodal treatment programs for prostate cancer [17]. Saffran et al. found that administration of anti-PSCA mAbs could inhibit metastasis to distant sites and restrain the growth of established orthotopic tumor, which could significantly prolong the survival time of tumor-bearing mice [18]. However, the therapeutic outcomes using anti-PSCA mAbs for prostate cancer patients are very poor and limited. There are few studies on radioimmunotherapy guided by anti-PSCA mAbs for prostate cancer. The interesting area indicating the region of interest has been used in many surveillance systems, such as medical image processing [19].

In this study, anti-PSCA mAbs labeled with I131 (I131-PSCA-mAb) were made to investigate the potential therapeutic efficacy of I131-PSCA-mAb for prostate cancer. The proliferation abilities, apoptosis and invasion abilities of PC-3 and LNCaP cells treated with I131-PSCA-mAb in vitro were measured by methyl thiazolyl tetrazolium (MTT) assay, flow cytometry and transwell culture, respectively. Furthermore, human prostate cancer xenograft nude mice models were established by injection of androgen-dependent LNCaP cells and androgen-independent PC-3 cells. The distribution and variation of I131-PSCA-mAb in the tumor-bearing nude mice over time were measured by single-photon emission computerized tomography (SPECT) and the ROI method. Tumor cell apoptosis was detected by the terminal-deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) technique.

Methods

Cell culture

Human prostate cancer PC-3 cell and LNCaP cell strains were purchased from Nanjing Keygen Biotechnology Co., Ltd. The PC-3 cells and LNCaP cells were maintained in RPMI-1640 and DMEM/F12 (GIBCO, USA) supplemented with 10% fetal calf serum (GIBCO, USA), respectively. All cells were incubated in a humidified air incubator with 5% CO2 at 37°C. The PC-3 cells and LNCaP cells at exponential growth phase were digested with 0.25% trypsin for inoculation.

Animals

All animal studies were approved by the China Ethics Committee and performed in accordance with the ethical standards. A total of 15 12-week-old male nude mice (BALB/c-nu/nu) were recruited for the study. The male nude mice were from the Model Animal Research Center of Nangjing University. The nude mice were raised under the sterile barrier system with constant temperature (25-27°C) and humidity (40-50%) as well as experimental conditions accorded with the specific pathogen-free (SPF) standard. The nude mice were freely fed with high-pressure-sterilized forage and water.

Establishment of prostate cancer models

The models of human prostate cancer were established in nude mice by orthotopic implantation. The PC-3 cells or LNCaP cells were inoculated into the anterior prostate of each nude mouse at the density of 2 × 107 cells/ml. The 15 male nude mice were randomly divided into three groups: the group inoculated with 100 μl LNCaP cells (n = 5), the group inoculated with 100 μl PC-3 cells (n = 5) and the control group inoculated with 100 μl normal saline (n = 5).

Labeling and identification of I131

The mouse anti-human PSCA IgG monoclonal antibodies (PSCA-mAb), which were specific to human orthotopic tumors in the mice and did not affect endogenous PSCA expression in these animals, were purchased from Sigma Co. in the USA. The labeling and identification of I131 in PSCA-mAb and control IgG were conducted at Shandong University.

Measurements of cell inhibitory rate, apoptosis and invasion

The PC-3 and LNCaP cells were divided into four groups treated with normal saline, I131-PSCA-mAb, I131-IgG or PSCA-mAb, respectively. The difference in proliferation ability of PC-3 and LNCaP cells treated with the above three drugs including I131-PSCA-mAb, I131-IgG and PSCA-mAb (2 ug/ul) in vitro was measured by MTT assay. Briefly, 100 μl cells with the density of 2 × 104 cells/ml was seeded into each well of a 96-well plate and incubated for 48 h. MTT (50 μl, 1 mg/ml) was added to each well, and the cells were incubated for 4 h. DMSO (150 μl) was later added to each well to solubilize the formazan crystals. The absorbance was read at 570 nm using a microplate reader. All determinations were carried out in triplicate. The inhibitory rate (IR) of the cell proliferation was calculated according to the equation: IR (%) = (1-A/A’) × 100% where A refers to the absorbance of the drug-treated group and A’ refers to the absorbance of the control group.

The difference in apoptosis of PC-3 and LNCaP cells treated with drugs in vitro was measured by an apoptosis assay kit according to the manufacturer’s instructions. AnnexinV-FITC (5 ul) was added to the cell suspension, and then propidium iodide (5 ul) was added after blending. The cells were incubated for 5–15 min at room temperature out of direct sunlight. Cell apoptosis was detected using flow cytometry (GUAVA, Millipore) within 1 h.

Cell invasion ability was determined using a transwell chamber (Corning, Mexico) with a pore size of 8.0 μm. Cells with the density of 1 × 105 cells/ml in serum-free medium were added to each insert. After being cultured for 10 h at 37°C, the cells that had invaded the membrane were fixed by 4% paraformaldehyde and stained with 0.1% crystal violet. Five fields were selected randomly from the central and surrounding membrane, and then cells in every field were counted. All determinations were carried out in triplicate.

SPECT for tumor-bearing nude mice

SPECT was performed on five tumor-bearing nude mice inoculated with androgen-independent PC-3 cells and five tumor-bearing nude mice inoculated with androgen-dependent LNCaP cells at 1 h, 4 h, 8 h, 12 h and 24 h after intravenous injection of 200 ul I131-PSCA-mAb (1 ug/ul) using a pinhole collimator. In order to block the uptake of I131 by the thyroid gland, nude mice were treated with a saturated solution of potassium iodide before the intravenous injection. The matrix was 128 × 128, and the zoom value was 1.33. The image data per frame were 2 × 105 pixels. The ratio of I131-PSCA-mAb in tumor to intramuscular I131-PSCA-mAb (T/NT) in the tumor-bearing nude mice with time was measured using the ROI method with GE Xeleris software.

Detection of tumor cell apoptosis

Apoptotic cells were detected by the TUNEL technique with an in situ cell death detection kit (Beyotime, China). The paraffin-embedded prostate tissues of the control group and experimental group were cut into 3-μm-thick sections and underwent routine deparaffinization and rehydration. Sections were incubated with the TUNEL reaction mixture containing terminal-deoxynucleotidyl transferase and label solution at 37°C for 1 h. Converted peroxidase (POD) was added later. 3, 3′-Diaminobenzidine (DAB) was used as a chromogen for final visualization.

Statistical analysis

The measurement data were expressed as mean ± standard deviation and analyzed by t-test using SPSS version 17.0 software (Chicago, IL, USA). Differences were significantly statistical at P <0.05.

Results

Cell inhibitory rate

The inhibitory rates of PC-3 and LNCaP cells treated with drugs were measured by MTT assay (Figure 1). Compared with the control group, the proliferations of PC-3 and LNCaP cells treated with I131-PSCA-mAb, PSCA-mAb or I131-IgG were inhibited to different degrees. The inhibitory rates of PC-3 and LNCaP cells reached the maximum of 84% and 80%, respectively, when cells were treated with I131-PSCA-mAb. The inhibitory rates of PC-3 and LNCaP cells treated with I131-PSCA-mAb were significantly higher than those of the cells treated with PSCA-mAb or I131-IgG (P < 0.05).

Figure 1
figure 1

The inhibitory rates of PC-3 and LNCaP cells treated with I131-PSCA-mAb, I131-IgG or PSCA-mAb (* P < 0.05, compared with the LNCaP cells treated with I131-PSCA-mAb; # P < 0.05, compared with the PC-3 cells treated with I131-PSCA-mAb).

Full size image

Cell apoptosis

The apoptosis of PC-3 and LNCaP cells treated with drugs in vitro was measured by flow cytometry (Figure 2). Compared with the control group, the apoptosis rates of PC-3 and LNCaP cells treated with I131-PSCA-mAb, PSCA-mAb or I131-IgG were gradually increased. The apoptosis rates of PC-3 and LNCaP cells reached the maximum of 50% and 46%, respectively, when cells were treated with I131-PSCA-mAb.

Figure 2
figure 2

The apoptosis of PC-3 and LNCaP cells treated with drugs. (a: LNCaP cells treated with normal saline; b: LNCaP cells treated with PSCA-mAb; c: LNCaP cells treated with I131-IgG; d: LNCaP cells treated with I131-PSCA-mAb; e: PC-3 cells treated with normal saline; f: PC-3 cells treated with PSCA-mAb; g: PC-3 cells treated with I131-IgG; h: PC-3 cells treated with I131-PSCA-mAb).

Full size image

Cell invasion ability

The invasion ability of PC-3 and LNCaP cells treated with drugs was determined by transwell culture (Figure 3). Compared with the control group, there was no significant difference in the invasion ability between the group treated with PSCA-mAb and the group treated with I131-IgG. When cells were treated with I131-PSCA-mAb, the number of PC-3 and LNCaP cells that had invaded the membrane was 36 and 34, respectively. The number of invaded PC-3 and LNCaP cells treated with I131-PSCA-mAb was significantly lower than that of the control group (P < 0.01).

Figure 3
figure 3

The invasion abilities of PC-3 and LNCaP cells treated with I131-PSCA-mAb, I131-IgG or PSCA-mAb (** P < 0.01, compared with the cells treated with normal saline).

Full size image

SPECT for tumor-bearing nude mice

The tumor-bearing nude mice inoculated with androgen-independent PC-3 cells or androgen-dependent LNCaP cells were examined by SPECT at 1 h, 4 h, 8 h, 12 h and 24 h after intravenous injection of I131-PSCA-mAb (Figure 4). The tumor developed clearly 1 h after intravenous injection, and the kidney, stomach and intestine had higher enhancement. The tumor enhancement region gradually increased over time, while the abdomen, blood and muscle enhancement decreased.

Figure 4
figure 4

The SPECT for tumor-bearing nude mice at 1 h, 4 h, 8 h, 12 h and 24 h after intravenous injection of I131-PSCA-mAb. (a: tumor-bearing nude mice inoculated with androgen-independent PC-3 cells; b: tumor-bearing nude mice inoculated with androgen-dependent LNCaP cells).

Full size image

The variation of I131-PSCA-mAb in the tumor-bearing nude mice over time was measured using the ROI method (Figure 5). The variation of T/NT with time was in accordance with the distribution in vivo. The T/NT of androgen-independent and androgen-dependent tumor-bearing nude mice increased with time and was highest at 4.2 and 4.4 after 8 h. The T/NT stayed above 3.0 after 12 h, and the tumor could still be observed after 24 h.

Figure 5
figure 5

The ratio of I 131 -PSCA-mAb in tumor to intramuscular I 131 -PSCA-mAb (T/NT) in the tumor-bearing nude mice at 1 h, 4 h, 8 h, 12 h and 24 h after intravenous injection of I 131 -PSCA-mAb.

Full size image

Tumor cell apoptosis

The prostate tissue sections of the control and the experimental groups were analyzed by the TUNEL method to detect tumor cell apoptosis. There were apoptotic cells in androgen-independent and -dependent nude mice treated with I131-PSCA-mAb, and the number of TUNEL-positive cells was obviously larger than that in the control group (Figure 6).

Figure 6
figure 6

The tumor cell apoptosis of tumor-bearing nude mice treated with I131-PSCA-mAb. (a: control group of androgen-dependent nude mice; b: androgen-dependent nude mice treated with I131-PSCA-mAb; c: control group of androgen-independent nude mice; d: androgen-independent nude mice treated with I131-PSCA-mAb).

Full size image

Discussion

PSCA is an ideal candidate for the detection or immunotherapy of prostate cancer because it has increased expression specificity for prostate cancer and has a specific cell surface location [12, 20, 21]. Radioimmunotherapy (RIT) uses monoclonal antibodies against tumor-specific antigens in conjunction with a particle-emitting radioisotope to deliver cytocidal ionizing radiation directly to the tumor [22]. In our study, the potential therapeutic efficacy of anti-PSCA mAbs in conjunction with I131 for prostate cancer was evaluated. We found that I131-PSCA-mAb showed great advantages in radioimmunotherapy and stronger positive anti-prostate tumor activity compared with I131-IgG and PSCA-mAb. Therefore, I131-based elimination of PSCA-producing cells seems to be a more efficient therapeutic method.

The immunotherapeutic efficacy of PSCA-mAb has been investigated by many studies considering PSCA as a putative target in a prostate cancer model, and the results of these studies have indicated that anti-PSCA antibodies have potential therapeutic roles for the treatment of prostate cancer [21, 23]. In our study, we found that PSCA-mAb could inhibit the growth, apoptosis and migration of PC-3 and LNCaP cells to some extent. Therefore, these results are consistent with previous reports on anti-PSCA-based immunotherapy. RIT, which can target the corresponding antigens via binding radionuclides to antibodies, has a promising role in the treatment of metastatic melanoma, ovarian cancer and metastatic colorectal cancer [24–26]. The characteristic and complex interactions among the tumor, host, antigen-antibody complex and radionuclide determine the effectiveness of RIT [27]. In this study, the inhibitory and apoptosis rates of PC-3 and LNCaP cells treated with I131-PSCA-mAb reached up to the maximum of 84%, 80% and 50%, 46%, respectively, which were obviously higher than in the cells treated with I131-IgG or PSCA-mAb. Therefore, I131-PSCA-mAb could effectively inhibit the proliferation of cancer cells and promote the apoptosis of cancer cells. Compared with the control group, the number of invaded PC-3 and LNCaP cells treated with I131-PSCA-mAb was significantly reduced, which indicated that the invasion abilities of tumor cells were significantly reduced by I131-PSCA-mAb.

Furthermore, the ratios of I131-PSCA-mAb in tumor to intramuscular I131-PSCA-mAb (T/NT) in androgen-independent and -dependent tumor-bearing nude mice increased with time, which demonstrated that I131-PSCA-mAb-targeted radioimmunotherapy may have few or minimal undesired toxic effects on the other tissues. The T/NT stayed above 3.0 after 12 h, and the tumor could still be observed after 24 h. Therefore, guided treatment for prostate cancer could be precisely conducted. What is more, the number of apoptotic cells in androgen-independent or -dependent nude mice treated with I131-PSCA-mAb was larger than that in the control group. That is to say, I131-PSCA-mAb-targeted radioimmunotherapy could effectively promote cancer cell apoptosis in tumor-bearing nude mice. However, PSCA-mAb might not be able to specifically target non-PSCA-expressing tumor cells. Therefore, the applicability of I131-PSCA-mAb treatment in humans needs to be further explored.

Conclusion

In conclusion, I131-PSCA-mAb has the potential to become a new targeted therapy drug for the radioimmunotherapeutic treatment of prostate cancer because it exhibited good targeting ability and efficacy and few side effects in nude mice models of human prostate cancer. We optimistically anticipate that I131-PSCA-mAb can be applied in clinical therapy.

Authors’ information

Shengqiang Yu and Fan Feng, the first two authors, should be regarded as joint first authors.

References

  1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60: 277–300. 10.3322/caac.20073

    Article  PubMed  Google Scholar 

  2. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, Levi F: Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol 2010, 21: 1323–1360. 10.1093/annonc/mdp530

    Article  CAS  PubMed  Google Scholar 

  3. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al.: Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18: 11–22. 10.1016/j.ccr.2010.05.026

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Calcagno F, Nguyen T, Dobi E, Villanueva C, Curtit E, Kim S, Montcuquet P, Kleinclauss F, Pivot X, Thiery-Vuillemin A: Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer. Clin Med Insights Oncol 2013, 7: 1–12.

    PubMed Central  CAS  PubMed  Google Scholar 

  5. Huggins CHC: Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1: 293–297.

    CAS  Google Scholar 

  6. Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002, 167: 948–951. discussion 952 10.1016/S0022-5347(02)80307-X

    Article  CAS  PubMed  Google Scholar 

  7. Hamberg P, Verhagen PC, De Wit R: When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer 2008, 44: 1193–1197. 10.1016/j.ejca.2008.04.005

    Article  CAS  PubMed  Google Scholar 

  8. Sternberg CN: Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann Oncol 2008, 19(Suppl 7):vii91-vii95.

    PubMed  Google Scholar 

  9. Gasent Blesa JM, Godoy MP, Esparcia MF, Molla SB, Magan BM, Sempere Ortells JM, Sanchez JL: PSA response to lenalidomide therapy in a pre-treated patient with metastatic prostate cancer refractory to hormones and chemotherapy: a case report. Case Rep Oncol 2012, 5: 181–186. 10.1159/000336481

    Article  PubMed Central  PubMed  Google Scholar 

  10. Moul JW: Variables in predicting survival based on treating “PSA-only” relapse. Urol Oncol 2003, 21: 292–304. 10.1016/S1078-1439(03)00103-0

    Article  PubMed  Google Scholar 

  11. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003, 21: 1232–1237. 10.1200/JCO.2003.06.100

    Article  PubMed  Google Scholar 

  12. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, et al.: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998, 95: 1735–1740. 10.1073/pnas.95.4.1735

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE: Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000, 19: 1288–1296. 10.1038/sj.onc.1203426

    Article  CAS  PubMed  Google Scholar 

  14. Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE: Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 2004, 171: 1117–1121. 10.1097/01.ju.0000109982.60619.93

    Article  CAS  PubMed  Google Scholar 

  15. Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE: Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 2005, 11: 2591–2596. 10.1158/1078-0432.CCR-04-1842

    Article  CAS  PubMed  Google Scholar 

  16. Saeki N, Gu J, Yoshida T, Wu X: Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res 2010, 16: 3533–3538. 10.1158/1078-0432.CCR-09-3169

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Ahmad S, Casey G, Sweeney P, Tangney M, O’Sullivan GC: Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther 2009, 17: 1101–1108. 10.1038/mt.2009.66

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A: Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A 2001, 98: 2658–2663. 10.1073/pnas.051624698

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Fasquel JB, Agnus V, Moreau J, Soler L, Marescaux J: An interactive medical image segmentation system based on the optimal management of regions of interest using topological medical knowledge. Comput Meth Programs Biomed 2006, 82: 216–230. 10.1016/j.cmpb.2006.04.004

    Article  Google Scholar 

  20. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ: Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003, 30: 667–676. 10.1016/S0093-7754(03)00358-0

    Article  CAS  PubMed  Google Scholar 

  21. Raff AB, Gray A, Kast WM: Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett 2009, 277: 126–132. 10.1016/j.canlet.2008.08.034

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Sharkey RM, Goldenberg DM: Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006, 56: 226–243. 10.3322/canjclin.56.4.226

    Article  PubMed  Google Scholar 

  23. Kiessling A, Wehner R, Füssel S, Bachmann M, Wirth MP, Schmitz M: Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers 2012, 4: 193–217. 10.3390/cancers4010193

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Zalutsky MR, Pozzi OR: Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging 2004, 48: 289–296.

    CAS  PubMed  Google Scholar 

  25. Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, et al.: A phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003, 9: 5842–5852.

    CAS  PubMed  Google Scholar 

  26. Dadachova E, Nosanchuk JD, Shi L, Schweitzer AD, Frenkel A, Nosanchuk JS, Casadevall A: Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci U S A 2004, 101: 14865–14870. 10.1073/pnas.0406180101

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Chamarthy MR, Williams SC, Moadel RM: Radioimmunotherapy of non-Hodgkin’s lymphoma: from the ’magic bullets’ to ‘radioactive magic bullets’. Yale J Biol Med 2011, 84: 391–407.

    PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the Sci-tech Development Project of Shandong Province (no. 2011GGH21841).

Author information

Authors and Affiliations

  1. Department of Urology, Yantai Yuhuangding Hospital Affiliated to Medical College of Qingdao University, NO.20 East Yuhuangding Road, 264000, Yantai, China

    Shengqiang Yu, Fan Feng, Ke Wang, Changping Men, Chunhua Lin, Qingzuo Liu, Diandong Yang & Zhenli Gao

Authors
  1. Shengqiang Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fan Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ke Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Changping Men
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chunhua Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qingzuo Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Diandong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhenli Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Diandong Yang or Zhenli Gao.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SQY, DDY and ZLG designed the experiments. FF, KW and QZL carried out and interpreted the experiments. SQY, CPM and CHL wrote the article. All authors read and approved the final manuscript.

Authors’ original submitted files for images

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( https://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Cite this article

Yu, S., Feng, F., Wang, K. et al. The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer. Eur J Med Res 18, 56 (2013). https://doi.org/10.1186/2047-783X-18-56

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/2047-783X-18-56

Keywords

European Journal of Medical Research

ISSN: 2047-783X

Contact us